Abstract Body

We verified the performance of Abeta misfolding as a prescreening plasma biomarker for AD as recently shown [1,2,3] with an extended observation period up to 17 years before clinical onset. Additionally, the structure biomarker was compared to the concentration biomarkers GFAP, NFL and ptau181 [4].

Baseline plasma samples of 308 subjects taken between 2000-2002 were analyzed using the infrared-immuno-sensor (iRIS) [3]. The obtained structure biomarker results were compared with GFAP, NFL and ptau181 levels measured with SIMOA.

All biomarkers showed significant alterations in the 17 year old baseline samples of later AD patients compared to the healthy control subjects [4]. However, the structure biomarker showed the best prognostic performance at 17-year follow-up relative to all concentration biomarkers. Additionally, a biomarker panel of the structure biomarker and GFAP levels showed an added value. Interestingly, the prognostic performance of ptau181 was limited to about 8 years before symptom onset. It could not predict AD conversion much more than 8 years in advance.

The structure plasma biomarker identifies individuals with high risk to develop AD up to 17 years before clinical onset [4]. This allows screening by a simple blood test of the aging population for prevention and early intervention in symptom-free stages.

1. Nabers A, et al. EMBO Mol. Med. 2018

2. Stockmann J and Verberk I, et al. Alz Res and Ther. 2020

3. Nabers A, et al. J. Biophotonics. 2016

4 . Léon Beyer and Hannah Stocker, Dan Rujescu, Bernd Holleczek, Julia Stockmann, Andreas Nabers, Hermann Brenner, Klaus Gerwert. submitted